Single dose high-dose rate (HDR) brachytherapy (BT) as monotherapy for localised prostate cancer: Early results of a UK national cohort study.

CONCLUSION: This is the largest cohort of single dose HDR brachytherapy patients treated with a single dose published to date. It shows that with 19 Gy there is 100% bRFS at 3 years in low risk patients but results in intermediate and high risk groups are less encouraging falling to 86% and 75% at 3 years with relapse predominantly in the prostate. Limited by the short follow up period of this study, the long-term outcomes of this single dose HDR approach remains uncertain. It is important to have close ongoing surveillance of this cohort as the data matures.
PMID: 32044166 [PubMed - as supplied by publisher]

Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - February 6, 2020 Category: Radiology Authors: Tharmalingam H, Tsang Y, Ostler P, Wylie J, Bahl A, Lydon A, Ahmed I, Elwell C, Nikapota AR, Hoskin PJ, National UK HDR Prostate Brachytherapy Database Tags: Radiother Oncol Source Type: research